臨床外科78巻1号

2023年01月発行

特集 外科医が知っておくべき！ 免疫チェックポイント阻害薬 総論

外科医にとっての免疫チェックポイント阻害薬

著者： 黒田晃弘¹² 小林由香利¹ 長岡孝治¹ 垣見和宏¹

所属機関： ¹東京大学医学部附属病院免疫細胞治療学講座 ²東京大学医学部附属病院胃食道外科

ページ範囲：P.6 - P.11

【ポイント】
◆がんに対する治療として，免疫チェックポイント阻害薬の適応が急速に拡大している．
◆腫瘍微小環境における免疫と代謝の関連が重要である．
◆周術期における患者の全身状態管理と同様の配慮が，免疫チェックポイント阻害薬治療にも必要である．

参考文献

1）Specenier P：Ipilimumab in melanoma. Expert Rev Anticancer Ther 16：811-826, 2016

2）Chen DS, Mellman I：Oncology meets immunology：the cancer-immunity cycle. Immunity 39：1-10, 2013

3）Turley SJ, Cremasco V, Astarita JL：Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Revi Immunol 15：669-682, 2015

4）Reina-Campos M, Moscat J, Diaz-Meco M：Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol 48：47-53, 2017

5）Turner SJ, Bennett TJ, La Gruta NL：CD8（＋）T-cell memory：the why, the when, and the how. Cold Spring Harb Perspect Biol 13：a038661, 2021

6）Franco F, Jaccard A, Romero P, et al：Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab 2：1001-1012, 2020

7）Wang X, He Q, Shen H, et al：Genetic and phenotypic difference in CD8（＋）T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma. J Med Genet 56：18-21, 2019

8）Capece D, Verzella D, Fischietti M, et al：Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol 2012：926321, 2012

9）Rowshanravan B, Halliday N, Sansom DM：CTLA-4：a moving target in immunotherapy. Blood 131：58-67, 2018

10）Zheng Y, Fang YC, Li J：PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett 18：5399-5407, 2019

11）Alsaab HO, Sau S, Alzhrani R, et al：PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy：mechanism, combinations, and clinical outcome. Front Pharmacol 8：561, 2017

12）Bader JE, Voss K, Rathmell JC：Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell 78：1019-1033, 2020

13）Vander Heiden MG, Cantley LC, Thompson CB：Understanding the Warburg effect：the metabolic requirements of cell proliferation. Science 324：1029-1033, 2009

14）Chang CH, Qiu J, O'Sullivan D, et al：Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162：1229-1241, 2015

15）Cortese N, Capretti G, Barbagallo M, et al：Metabolome of pancreatic juice delineates distinct clinical profiles of pancreatic cancer and reveals a link between glucose metabolism and PD-1（＋）cells. Cancer Immunol Res 8：493-505, 2020

16）Palit V, Phillips RM, Puri R, et al：Expression of HIF-1α and Glut-1 in human bladder cancer. Oncol Rep 14：909-913, 2005

17）Scharping NE, Rivadeneira DB, Menk AV, et al：Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 22：205-215, 2021

18）Gerweck LE, Seetharaman K：Cellular pH gradient in tumor versus normal tissue：potential exploitation for the treatment of cancer. Cancer Res 56：1194-1198, 1996

19）Corbet C, Feron O：Tumour acidosis：from the passenger to the driver's seat. Nat Rev Cancer 17：577-593, 2017